MOTS-C vs SS-31: Mitochondrial Peptides in Research
MOTS-C and SS-31 represent two of the most actively investigated mitochondria-targeting peptides in current preclinical research. Both are studied for their interaction with mitochondrial biology, but they differ fundamentally in their origin, mechanism of action, and research applications. This comparison provides researchers with a structured overview of each compound and the questions they are best suited to address in laboratory settings.
For contextual background, see our guide on research peptides Canada and review our quality and purity standards.
What is MOTS-C?
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino acid peptide encoded within mitochondrial DNA rather than nuclear DNA — making it a mitochondria-derived peptide (MDP) of the mitochondrial ribosomal RNA gene. Its discovery in 2015 represented a significant finding in the field of mitochondrial biology, as it demonstrated that the mitochondrial genome encodes functionally active signalling peptides that can act in trans, i.e., travel from the mitochondria to the nucleus or be secreted into circulation.
MOTS-C’s primary proposed mechanism involves AMPK (AMP-activated protein kinase) pathway activation. Research has investigated how MOTS-C affects cellular metabolic homeostasis, with particular attention to:
- AMPK activation: MOTS-C appears to activate AMPK, the cell’s master energy sensor, promoting catabolic processes and increasing metabolic flexibility in preclinical models.
- Nuclear translocation: Under metabolic stress conditions, MOTS-C translocates from the mitochondria or cytoplasm to the nucleus, where it has been found to modulate gene expression through interaction with the ARE (antioxidant response element) pathway.
- Folate cycle disruption mitigation: MOTS-C has been studied in models where it appears to mitigate the adverse metabolic consequences of folate cycle perturbation — a metabolic stress pathway relevant to aging research.
- Insulin sensitivity models: Preclinical studies have investigated MOTS-C in models of insulin resistance, observing effects on glucose uptake in skeletal muscle-derived cell lines.
Read our MOTS-C compound guide for deeper mechanistic background. Our MOTS-C 10mg is available for qualified researchers.
What is SS-31?
SS-31 (also known as Elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller — hence the “SS” designation. Its sequence is D-Arg-2′,6′-Dmt-Lys-Phe-NH2, featuring alternating aromatic and basic residues that confer specific targeting properties. SS-31 is a member of the Szeto-Schiller (SS) peptide family developed specifically to target the inner mitochondrial membrane.
The primary mechanism of SS-31 centres on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane, where it plays structural and functional roles in the respiratory chain. Research has established that:
- Cardiolipin binding: SS-31 binds directly to cardiolipin at the inner mitochondrial membrane through electrostatic interactions, concentrating at the membrane regardless of mitochondrial electrical potential.
- Electron transport chain support: By binding cardiolipin and stabilizing its interaction with cytochrome c, SS-31 is hypothesized to support efficient electron transfer through Complex IV and reduce reactive oxygen species (ROS) generation from the electron transport chain.
- Mitochondrial morphology: Research has examined SS-31’s effects on mitochondrial cristae architecture and membrane integrity in cellular aging and ischemia models.
- ATP production: Preclinical studies in models of mitochondrial dysfunction have measured changes in ATP production efficiency following SS-31 treatment.
SS-31 has undergone preclinical and clinical investigation, with research programs examining it in models of heart failure, renal ischemia, and age-related mitochondrial dysfunction. See our SS-31 compound guide for full context. Our SS-31 10mg is available for laboratory use.
Mechanism Comparison Table
| Feature | MOTS-C | SS-31 |
|---|---|---|
| Origin | Mitochondria-derived peptide (mtDNA encoded) | Synthetic Szeto-Schiller peptide (chemically designed) |
| Molecular Type | 16-amino acid mitokine | Tetrapeptide (D-Arg-2′,6′-Dmt-Lys-Phe-NH2) |
| Primary Target | AMPK pathway; nuclear gene regulation via ARE | Inner mitochondrial membrane cardiolipin |
| Mechanism | AMPK activation, metabolic gene regulation, stress signalling | Cardiolipin stabilization, ETC efficiency, cristae integrity |
| Mitochondrial Entry Mechanism | Endogenous mitokine; cytoplasm-to-nucleus shuttling | Accumulates at inner mitochondrial membrane via charge |
| Primary Research Area | Metabolic regulation, insulin sensitivity, aging metabolism | Mitochondrial bioenergetics, ischemia models, ETC dysfunction |
| Research Stage | Primarily preclinical; in vitro and animal models | Preclinical and early clinical investigation |
Research Application Comparison
MOTS-C research applications are concentrated in metabolic biology and the signalling interface between mitochondria and nuclear gene expression. Researchers investigating AMPK-dependent metabolic pathways, mitohormesis (beneficial stress signalling from mitochondria), or the molecular biology of exercise adaptation have used MOTS-C to probe signalling mechanisms. The compound’s nuclear translocation under stress conditions makes it particularly interesting for studies on mitochondrial-nuclear communication. Research programs investigating the biology of metabolic aging find MOTS-C relevant because its circulating levels have been reported to decline with age in published studies.
SS-31 research applications are anchored in mitochondrial bioenergetics and the structural integrity of the inner mitochondrial membrane. Researchers investigating ischemia-reperfusion injury, models of heart failure with preserved ejection fraction, renal tubular cell biology, or direct dysfunction of the electron transport chain have employed SS-31 as a tool compound. Its specific cardiolipin binding provides a mechanistically targeted approach to studying inner mitochondrial membrane function that is not achievable with broadly acting antioxidants.
Both compounds are relevant to aging biology research, but from different angles — MOTS-C through metabolic signalling and nuclear gene regulation, SS-31 through biophysical stabilization of the electron transport chain architecture.
Frequently Asked Questions
What is the key difference between MOTS-C and SS-31 in research?
The key difference is mechanistic: MOTS-C activates the AMPK metabolic signalling pathway and can translocate to the nucleus to modulate gene expression, making it a signalling peptide studied in metabolic and aging biology. SS-31 binds directly to cardiolipin on the inner mitochondrial membrane to stabilize electron transport chain function, making it a structural/bioenergetics tool for mitochondrial dysfunction research. They target different aspects of mitochondrial biology and are not mechanistic alternatives to one another.
What makes MOTS-C unique among mitochondrial research peptides?
MOTS-C is uniquely significant because it is encoded by mitochondrial DNA rather than nuclear DNA — one of only a small number of functionally active signalling peptides known to originate from the mitochondrial genome. This makes it a mitokine (a mitochondria-derived hormone-like peptide) that can communicate cellular energy status systemically. Its discovery challenged the established view that mitochondrial DNA encodes only structural components of the respiratory chain, opening a new area of research into mitochondrial-to-nuclear and mitochondrial-to-systemic signalling.
What research models are most appropriate for SS-31?
SS-31 has been investigated in multiple research model systems, with the strongest evidence base in cardiac ischemia-reperfusion models, renal ischemia models, and in vitro models of mitochondrial dysfunction induced by electron transport chain inhibitors. Researchers studying cristae morphology, cardiolipin oxidation, cytochrome c release, or ATP production efficiency in the context of mitochondrial disease models have used SS-31 as a research tool. It has also entered clinical investigation for heart failure with preserved ejection fraction.
Are MOTS-C and SS-31 studied together in research?
Combination studies using both MOTS-C and SS-31 are not well-established in the current literature, as they target fundamentally different aspects of mitochondrial function. However, research programs comprehensively characterizing mitochondrial health may include both as orthogonal tools — MOTS-C to interrogate upstream metabolic signalling and nuclear communication, SS-31 to assess inner membrane integrity and bioenergetic efficiency. Visit our research peptides Canada page for our full catalog of mitochondrial research compounds.
⚠️ Research Use Only: All content on this page is intended strictly for educational and informational purposes. These compounds are not approved by Health Canada or any regulatory agency for human therapeutic use. TrueCanPeptides supplies research-grade compounds to qualified researchers only. This is not medical advice. Do not use any information here for self-administration, diagnosis, or treatment. Consult a licensed healthcare professional for any medical concerns.